SAB Biotherapeutics Inc (SABS) Stock Analysis

SAB Biotherapeutics Inc (SABS) is a publicly traded company in the HEALTHCARE sector. It trades at $3.48, carries a market capitalization of $279.09M. This page summarizes the public market data, fundamentals, and frequently asked questions for SABS, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

SAB Biotherapeutics Inc currently has a Neutral sentiment score of 0.12.

About SAB Biotherapeutics Inc

SAB Biotherapeutics Inc. is an innovative biopharmaceutical company focused on developing advanced immunotherapies targeting infectious diseases, autoimmune disorders, and oncology. Headquartered in Sioux Falls, South Dakota, with a strategic office in Cambridge, Massachusetts, the company leverages its proprietary technology platform to create therapeutic antibodies derived from genetically engineered cows. These uniquely produced antibodies aim to provide groundbreaking solutions in areas w...

GNG Research Analysis

GNG Research scores SAB Biotherapeutics Inc (SABS) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for SABS.

Frequently Asked Questions

Does SABS pay dividends?

SAB Biotherapeutics Inc (SABS) does not currently pay a regular dividend.

What is SABS's market cap?

SAB Biotherapeutics Inc (SABS) has a market capitalization of $279.09M with a current stock price of $3.48.